Future studies incorporating additional models, such as myocardial infarction or ischemia–reperfusion models, would provide complementary insights into the broader spectrum of CHD pathology and further validate the roles of DHX36 and GPR68 across different disease contexts. This evidence concerns the gene DHX36 and myocardial infarction.